Two years ago, I’ve already
posted about sirukumab (formerly known as CNTO 136), which is a human anti-IL-6
MAB. B. Hsu and colleagues presented a phase 2 study. I asked myself, if there is
a market for sirukumab in rheumatoid arthritis, as tocilizumab is already there
(and now with an SC option) sirukumab needs methotrexate as co-medication.
At the EULAR 2014 Meeting
in Paris there hasn’t been a study on sirukumab on rheumatoid arthritis. But
there has been a study on lupus nephritis.
[OP0047]
R. van Vollenhoven and
colleagues presented a study: “A PHASE 2, MULTICENTER, RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF SIRUKUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS”. Conclusions:
IL-6 inhibition with sirukumab in pts with active lupus nephritis did not
result in a median improvement in proteinuria, however approximately 15-20% of
treated patients did show a notable reduction in proteinuria. A high frequency of
serious adverse events was observed in this population of immunosuppressed patients
with refractory lupus nephritis.” Read between the lines. Sirukumab doesn’t
seem to be doing good job.
Does this dim the outlook
for sirukumab? Maybe not. The SIRROUND-LTE study on long-term safety and efficacy
of sirukumab in rheumatoid arthritis (a phase 3 study) is still recruiting. Therefore
we still have to wait, even if there wasn’t new data at the EULAR 2014 Meeting.
Link:
No comments:
Post a Comment